It is very uncertain whether FLUPHENAZINE DECANAOTE changes leaving the study early compared with FLUPHENAZINE ENANTHATE (very low certainty).
FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty).
It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).